|
Neoplastic Cell Transformation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis.
|
21750348 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PHLPP1 (PH domain and leucine rich repeat protein phosphatase 1) is a newly identified family of Ser/Thr phosphatases that catalyzes the dephosphorylation of a conserved regulatory motif of the AGC kinases resulting in a tumor suppressive function, while CDKN1B/p27 also acts as a tumor suppressor by regulating cell cycle, senescence, apoptosis, and cell motility.
|
30821592 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PH domain leucine-rich repeat-containing protein phosphatase 1 (PHLPP1) is known to be a tumour suppressor.
|
30092222 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our study identified a tumor suppressor role of PHLPP in suppressing cell motility by negatively regulating integrin expression in pancreatic cancer cells.
|
26760962 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PHLPP1 expression in human glioma was associated negatively with the severity of the tumor and inflammatory cytokines. siRNA PHLPP1 could increase the levels of inflammatory cytokines in U251 glioma cells while PHLPP1 addition could inhibit significantly inflammatory cytokines.
|
26971226 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ability of miR-199a-5p and miR-375 to target PHLPP1 (PH domain and leucine-rich repeat protein phosphatase 1), a tumor suppressor that negatively regulates the AKT pathway, accounts, at least in part, for their drug-resistance activity.
|
26107137 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It was PHLPP1 but not PHLPP2 that was significantly related to the tumor T stage.
|
25793736 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increasing PHLPP expression or inhibiting miR-495 expression can induce apoptosis and suppress tumor growth in GBC xenograft model in nude mice.
|
25895131 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study we have investigated the relationship between Usp12, PHLPP and PHLPPL tumour suppressors in the regulation of AR transcriptional activity in prostate cancer (PC).
|
25216524 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas Apc(Min) mice developed mostly low-grade adenomas, 20% of the tumors that developed in Apc(Min)/Phlpp1(-/-) mice were invasive adenocarcinomas.
|
24530606 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PHLPP, a novel family of Ser/Thr protein phosphatases, functions as a tumor suppressor in colon cancers.
|
24061475 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study reveals functional and mechanistic links between miRNA-224 and the tumor suppressors PHLPP1 and PHLPP2 in the pathogenesis of colorectal cancer. miR-224 not only plays important roles in the regulation of cell proliferation and tumor growth in colorectal cancer, but also has potential as a prognostic marker or therapeutic target for colorectal cancer.
|
23846336 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AKT signaling is constitutively activated in various cancers, due in large part to loss-of-function in the PTEN and PHLPP phosphatases that act as tumor suppressor genes.
|
23856247 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1), which terminates Akt signaling by directly dephosphorylating and inactivating Akt, has been identified as a tumor suppressor.
|
22426999 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rather, the defect arises from altered localization of β-TrCP1; in astrocytoma cell lines and in normal brain tissue the E3 ligase is predominantly cytoplasmic, whereas in glioblastoma cell lines and patient-derived tumor neurospheres, the E3 ligase is confined to the nucleus and thus spatially separated from PHLPP1, which is cytoplasmic.
|
21454620 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We show that Phlpp1-loss causes neoplasia and, on partial Pten-loss, carcinoma in mouse prostate.
|
21840483 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous studies indicated a tumor suppressor role of both PHLPP isoforms in colon cancer.
|
21177869 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.
|
20861921 |
2010 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Thus, PHLPP1 provides a proofreading step that maintains the fidelity of PKC autoinhibition and reveals a prominent loss-of-function mechanism in cancer by suppressing the steady-state levels of PKC.
|
30904392 |
2019 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Altered Phlpp1 levels are associated with cancer and degenerative diseases such as osteoarthritis.
|
29775231 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Both PHLPP1 and PHLPP2 are commonly deleted in human cancers, supporting a tumor suppressive role.
|
27913677 |
2016 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Many factors regulate cancer cell apoptosis, among which Survivin has a strong anti-apoptotic effect and PHLPP is a tumor suppressor gene that can induce significant apoptosis.
|
25895131 |
2015 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt.
|
24703948 |
2014 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The frequent deletion of PHLPP in cancer, coupled with the development of prostate tumors in mice lacking PHLPP1, identifies PHLPP as a novel tumor suppressor.
|
22144674 |
2012 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Thus, PHLPP1 provides a proofreading step that maintains the fidelity of PKC autoinhibition and reveals a prominent loss-of-function mechanism in cancer by suppressing the steady-state levels of PKC.
|
30904392 |
2019 |